FTO contributes to drug resistance in various cancers, including cervical cancer (Zhou et al., 2018), gastric cancer (Feng et al., 2021), melanoma (Yang et al., 2019), breast cancer (Wang et al., 2021), leukemia (Yan et al., 2018), colorectal cancer (Zhao et al., 2021), bladder cancer (Wen et al., 2020), and glioma (Xiao et al., 2020). This evidence concerns the gene FTO and colorectal cancer.